Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

New drug combination effective for patients with advanced ovarian cancer

Science Daily - 15 Feb 2022 01:33
A new study shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone.
Full Article at Science Daily

More Science News
1
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard